vs
盛美半导体（ACMR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
盛美半导体的季度营收约是Orthofix Medical Inc.的1.1倍（$244.4M vs $219.9M），盛美半导体净利率更高（3.3% vs -1.0%，领先4.3%），盛美半导体同比增速更快（9.4% vs 2.0%），盛美半导体自由现金流更多（$20.1M vs $16.8M），过去两年盛美半导体的营收复合增速更高（26.7% vs 8.0%）
盛美半导体（ACM Research, Inc.）是全球领先的半导体制造设备供应商，专注于研发、生产及销售晶圆湿法处理相关设备，覆盖清洗、电镀、刻蚀等品类，产品广泛应用于逻辑、存储、功率等各类先进芯片的生产流程，服务全球多地区芯片制造企业。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ACMR vs OFIX — 直观对比
营收规模更大
ACMR
是对方的1.1倍
$219.9M
营收增速更快
ACMR
高出7.4%
2.0%
净利率更高
ACMR
高出4.3%
-1.0%
自由现金流更多
ACMR
多$3.3M
$16.8M
两年增速更快
ACMR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $244.4M | $219.9M |
| 净利润 | $8.0M | $-2.2M |
| 毛利率 | 40.9% | 71.1% |
| 营业利润率 | 9.4% | 0.2% |
| 净利率 | 3.3% | -1.0% |
| 营收同比 | 9.4% | 2.0% |
| 净利润同比 | -74.1% | 92.4% |
| 每股收益（稀释后） | $0.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACMROFIX
| Q4 25 | $244.4M | $219.9M | ||
| Q3 25 | $269.2M | $205.6M | ||
| Q2 25 | $215.4M | $203.1M | ||
| Q1 25 | $172.3M | $193.6M | ||
| Q4 24 | $223.5M | $215.7M | ||
| Q3 24 | $204.0M | $196.6M | ||
| Q2 24 | $202.5M | $198.6M | ||
| Q1 24 | $152.2M | $188.6M |
净利润ACMROFIX
| Q4 25 | $8.0M | $-2.2M | ||
| Q3 25 | $35.9M | $-22.8M | ||
| Q2 25 | $29.8M | $-14.1M | ||
| Q1 25 | $20.4M | $-53.1M | ||
| Q4 24 | $31.1M | $-29.1M | ||
| Q3 24 | $30.9M | $-27.4M | ||
| Q2 24 | $24.2M | $-33.4M | ||
| Q1 24 | $17.4M | $-36.0M |
毛利率ACMROFIX
| Q4 25 | 40.9% | 71.1% | ||
| Q3 25 | 42.0% | 72.2% | ||
| Q2 25 | 48.5% | 68.7% | ||
| Q1 25 | 47.9% | 62.8% | ||
| Q4 24 | 49.6% | 69.0% | ||
| Q3 24 | 51.4% | 68.7% | ||
| Q2 24 | 47.8% | 67.8% | ||
| Q1 24 | 52.0% | 67.5% |
营业利润率ACMROFIX
| Q4 25 | 9.4% | 0.2% | ||
| Q3 25 | 10.7% | -8.3% | ||
| Q2 25 | 14.7% | -7.9% | ||
| Q1 25 | 15.0% | -25.2% | ||
| Q4 24 | 19.7% | -5.3% | ||
| Q3 24 | 21.7% | -9.6% | ||
| Q2 24 | 18.6% | -12.5% | ||
| Q1 24 | 16.6% | -15.6% |
净利率ACMROFIX
| Q4 25 | 3.3% | -1.0% | ||
| Q3 25 | 13.3% | -11.1% | ||
| Q2 25 | 13.8% | -6.9% | ||
| Q1 25 | 11.8% | -27.4% | ||
| Q4 24 | 13.9% | -13.5% | ||
| Q3 24 | 15.2% | -13.9% | ||
| Q2 24 | 12.0% | -16.8% | ||
| Q1 24 | 11.5% | -19.1% |
每股收益（稀释后）ACMROFIX
| Q4 25 | $0.11 | $-0.05 | ||
| Q3 25 | $0.52 | $-0.57 | ||
| Q2 25 | $0.44 | $-0.36 | ||
| Q1 25 | $0.30 | $-1.35 | ||
| Q4 24 | $0.47 | $-0.76 | ||
| Q3 24 | $0.45 | $-0.71 | ||
| Q2 24 | $0.35 | $-0.88 | ||
| Q1 24 | $0.26 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $792.9M | $82.0M |
| 总债务越低越好 | $214.0M | — |
| 股东权益账面价值 | $1.5B | $450.0M |
| 总资产 | $2.9B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ACMROFIX
| Q4 25 | $792.9M | $82.0M | ||
| Q3 25 | $1.1B | $62.9M | ||
| Q2 25 | $463.2M | $65.6M | ||
| Q1 25 | $475.6M | $58.0M | ||
| Q4 24 | $426.8M | $83.2M | ||
| Q3 24 | $353.8M | $30.1M | ||
| Q2 24 | $343.6M | $26.4M | ||
| Q1 24 | $230.0M | $27.0M |
总债务ACMROFIX
| Q4 25 | $214.0M | — | ||
| Q3 25 | $242.0M | $157.2M | ||
| Q2 25 | $225.1M | $157.0M | ||
| Q1 25 | $202.5M | $156.9M | ||
| Q4 24 | $150.0M | $157.0M | ||
| Q3 24 | $150.0M | $118.5M | ||
| Q2 24 | $90.5M | $118.0M | ||
| Q1 24 | $60.0M | $118.2M |
股东权益ACMROFIX
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.4B | $442.5M | ||
| Q2 25 | $986.5M | $458.3M | ||
| Q1 25 | $949.1M | $458.3M | ||
| Q4 24 | $904.6M | $503.1M | ||
| Q3 24 | $888.2M | $525.9M | ||
| Q2 24 | $833.2M | $546.0M | ||
| Q1 24 | $796.2M | $570.3M |
总资产ACMROFIX
| Q4 25 | $2.9B | $850.6M | ||
| Q3 25 | $2.8B | $832.6M | ||
| Q2 25 | $2.0B | $837.2M | ||
| Q1 25 | $1.9B | $823.1M | ||
| Q4 24 | $1.9B | $893.3M | ||
| Q3 24 | $1.8B | $867.9M | ||
| Q2 24 | $1.7B | $882.0M | ||
| Q1 24 | $1.6B | $906.0M |
负债/权益比ACMROFIX
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | 0.36× | ||
| Q2 25 | 0.23× | 0.34× | ||
| Q1 25 | 0.21× | 0.34× | ||
| Q4 24 | 0.17× | 0.31× | ||
| Q3 24 | 0.17× | 0.23× | ||
| Q2 24 | 0.11× | 0.22× | ||
| Q1 24 | 0.08× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $20.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 8.2% | 7.6% |
| 资本支出强度资本支出/营收 | 5.6% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.21× | — |
| 过去12个月自由现金流最近4个季度 | $-66.6M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ACMROFIX
| Q4 25 | $33.9M | $27.7M | ||
| Q3 25 | $-4.6M | $12.4M | ||
| Q2 25 | $-44.9M | $11.6M | ||
| Q1 25 | $5.3M | $-18.4M | ||
| Q4 24 | $88.6M | $23.7M | ||
| Q3 24 | $11.9M | $11.7M | ||
| Q2 24 | $61.6M | $9.0M | ||
| Q1 24 | $-9.6M | $-18.6M |
自由现金流ACMROFIX
| Q4 25 | $20.1M | $16.8M | ||
| Q3 25 | $-15.6M | $2.5M | ||
| Q2 25 | $-59.6M | $4.5M | ||
| Q1 25 | $-11.4M | $-25.1M | ||
| Q4 24 | $77.2M | $15.2M | ||
| Q3 24 | $-20.6M | $6.3M | ||
| Q2 24 | $48.5M | $-360.0K | ||
| Q1 24 | $-35.1M | $-29.1M |
自由现金流率ACMROFIX
| Q4 25 | 8.2% | 7.6% | ||
| Q3 25 | -5.8% | 1.2% | ||
| Q2 25 | -27.7% | 2.2% | ||
| Q1 25 | -6.6% | -13.0% | ||
| Q4 24 | 34.5% | 7.0% | ||
| Q3 24 | -10.1% | 3.2% | ||
| Q2 24 | 24.0% | -0.2% | ||
| Q1 24 | -23.0% | -15.4% |
资本支出强度ACMROFIX
| Q4 25 | 5.6% | 4.9% | ||
| Q3 25 | 4.1% | 4.8% | ||
| Q2 25 | 6.8% | 3.5% | ||
| Q1 25 | 9.7% | 3.5% | ||
| Q4 24 | 5.1% | 4.0% | ||
| Q3 24 | 16.0% | 2.7% | ||
| Q2 24 | 6.5% | 4.7% | ||
| Q1 24 | 16.7% | 5.6% |
现金转化率ACMROFIX
| Q4 25 | 4.21× | — | ||
| Q3 25 | -0.13× | — | ||
| Q2 25 | -1.51× | — | ||
| Q1 25 | 0.26× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 2.54× | — | ||
| Q1 24 | -0.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACMR
| Total Single Wafer And Semi Critical Cleaning Equipment | $159.9M | 65% |
| ECP Front End And Packaging Furnace And Other Technologies | $64.1M | 26% |
| Advanced Packaging Exclude ECP Services Spares | $20.5M | 8% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
